Eli Lilly's Mounjaro Launch Sparks Competition in India's Weight-Loss Drug Market

Spread the love

March 20: Eli Lilly and Company, a leading U.S.-based pharmaceutical firm, launched its new weight-reduction and type 2 diabetes medication, Mounjaro (tripeptide), in India. The launch follows approval by the Central Drugs Standard Control Organisation (CDSCO), a big step in the fight against diabetes and obesity in the country.

What is Mounjaro (Tirzepatide)?

Mounjaro, which is chemically referred to as tripeptide, is a new drug that acts on both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The dual mechanism of action increases insulin secretion and reduces hunger, resulting in better blood glucose control and remarkable weight loss. The medication is taken once weekly through a subcutaneous injection.

Pricing and Accessibility Issues

To bring Mounjaro within reach of a wider section of the population in India, Eli Lilly has launched the drug at competitive prices:

2.5 mg vial: Priced at ₹3,500.
5 mg vial: Its cost is fixed at ₹4,375.

These India-specific prices are considerably lower than those in Western markets, an indication of Eli Lilly’s desire to make access to innovative treatments available in developing nations.

The Existing Condition of Diabetes and Obesity in India

India is facing a growing health threat, with approximately 101 million individuals with diabetes—a number that is poised to grow due to the growing obesity rates. Obesity is one of the most dangerous risk factors for type 2 diabetes, and thus good control of weight is essential to help contain the epidemic of the disease.

The Horizon Of Market Competition and Future Prospects

Eli Lilly’s launch of Mounjaro places the company at the forefront of the pack compared to its competitors in the fast-expanding and more profitable market for anti-obesity drugs in India. Aside from Eli Lilly’s major move, it is interesting to note that some other drug firms are also seriously gearing up to join this profitable sector:

Novo Nordisk: Aims to roll out its weight-loss medication Wegovy (semaglutide) in India by 2026, after its patent runs out in the nation. – Sun Pharmaceutical: Working on liraglutide for weight loss and type 2 diabetes, with a projected launch in the next few years.
Biocon: The firm is developing a version of semaglutide, intending to market it as soon as the medicine goes off-patent next year.

Apart from this, some leading players like Zydus Lifesciences, Cipla, Dr. Reddy’s Laboratories, Lupin Pharmaceuticals, Natco Pharma, Mankind Pharma, and Aurobindo Pharma are also developing generic forms of the drug semaglutide. These players expect a massive demand for such drugs given the fast-developing obesity treatment business in India.

International Consequences

The global market for obesity drugs is predicted to reach $150 billion annually by the early 2030s. Strategic pricing and early market penetration by Eli Lilly in the Indian market can have a tremendous influence on its global market share as well as profitability. The company may, however, face competition from licensed copies of their drug approved in other developing countries, which can influence their market dominance.

Conclusion

The recent release of Mounjaro by Eli Lilly in India is a genuine landmark moment in the changing dynamics of healthcare in India. The new medicine offers a new and potent remedy for those who endure the complications of type 2 diabetes and obesity. That Eli Lilly is the first major pharmaceutical firm to introduce such a revolutionary medicine in the Indian market opens the door to greater competition among pharmaceutical firms while driving innovation in the weight-loss medicine market. This shift has the potential to dramatically enhance health outcomes for millions of individuals struggling with these serious health concerns.

Keep Reading Questiqa.biz